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Background: Adult skeletal muscle myogenesis depends on the activation of satellite cells that have the potential
to differentiate into new fibers. Gamma-oryzanol (GO), a commercially available nutriactive phytochemical, has
gained global interest on account of its muscle-building and regenerating effects. Here, we investigated GO for its
potential influence on myogenesis, using equine satellite cell culture model, since the horse is a unique animal,
bred and exercised for competitive sport. To our knowledge, this is the first report where the global gene
expression in cultured equine satellite cells has been described.
Methods: Equine satellite cells were isolated from semitendinosus muscle and cultured until the second day of
differentiation. Differentiating cells were incubated with GO for the next 24 h. Subsequently, total RNA from GO-
treated and control cells was isolated, amplified, labeled, and hybridized to two-color Horse Gene Expression
Microarray slides. Quantitative PCR was used for the validation of microarray data.
Results: Our results revealed 58 genes with changed expression in GO-treated vs. control cells. Analysis of
expression changes suggests that various processes are reinforced by GO in differentiating equine satellite cells,
including inhibition of myoblast differentiation, increased proliferation and differentiation, stress response, and
increased myogenic lineage commitment.
Conclusions: The present study may confirm putative muscle-enhancing abilities of GO; however, the collective
role of GO in skeletal myogenesis remains equivocal. The diversity of these changes is likely due to heterogenous
growth rate of cells in primary culture. Genes identified in our study, modulated by the presence of GO, may
become potential targets of future research investigating impact of this supplement in skeletal muscle on
proteomic and biochemical level.
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Since horses were domesticated on the Eurasian Steppe
over 6000 years ago, they had been selected for strength,
speed, and endurance exercise [23]. Nowadays in
Europe, working horses are very seldom used for farm-
ing purposes; they became exclusively domestic animals
exercised for competitive sport. In both equine and* Correspondence: tomasz_sadkowski@sggw.pl
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(http://creativecommons.org/publicdomain/zehuman athletes, nutritional ergogenic aids have been
used to improve physical ability with an appropriate
training regimen. Although training increases physical
condition, the ease of taking a nutritional additive to im-
prove training results explains the demand for supple-
mentation, which may increase mechanical energy of
work, delay onset of fatigue, and improve neuromuscular
coordination [26].
Gamma-oryzanol (GO) is a unique mixture of triter-
pene alcohol and sterol ferulates present in rice bran oil,
a by-product of rice processing. GO has a wide range oficle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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vention of coronary atherosclerosis and anticancerogenic
and antidiabetic action [28]; however, in our study, we
focused on the anabolic properties of GO.
GO has been shown to be very safe with no major side
effects being reported in either animal or human studies
and is a popular ergogenic aid approved for commercial
use in the USA [17]. Moreover, GO is often used by
veterinary practitioners in order to improve muscle mass
gain and recovery in horses. It was temporarily
accounted as a prohibited substance by the Federation
Equestre Internationale (FEI) unit governing rules of fair
play in equestrian competition (FEI Veterinary Regula-
tions 11th edition, 1st January 2009) [44].
Despite this, only a few studies of ergogenic use of GO
were described in the peer-reviewed literature. In one
study, authors looked on the resistance-weight-trained
male athletes supplemented with 500 mg of GO daily
[19]. However, this study failed to demonstrate any effect
of GO on training performance. In a recent study,
Eslami et al. [17] revealed that 600 mg/day of GO sup-
plementation changed muscular strength in young
healthy males in the 9-week resistance training without
any significant alteration in anthropometric measure-
ments. Ostaszewski et al. [49] showed that GO supple-
mentation prevented exercise-induced muscle damage in
thoroughbred race horses during 16 weeks of training.
Animals received 3 g of GO a day. However, no paper
describing GO’s influence on equine satellite cells was
published.
Skeletal muscle satellite cells (SC) are mononucleated
cells located under the basal lamina of myofiber. They play
an indispensable role during adult skeletal muscle regen-
eration and hypertrophy. SC are quiescent during most of
their normal adult life. Upon activation, they proliferate,
differentiate, and finally fuse with adjacent muscle fiber or
with other satellite cells to form new multinucleated fibers
[40]. The procedure of harvesting satellite cells from
equine muscles was first described in 1992 [22], but until
now, except for that single report, studies concerning
equine satellite cells in vitro are scarce. Previous transcrip-
tomic analyses in horses were conducted on peripheral
blood cells and muscle samples obtained by muscular bi-
opsy; thus, our report is the first trial where the global
gene expression in cultured equine satellite cells has been
described [51]. Satellite cells require an activation signal to
proliferate and differentiate and can be controlled by
a variety of hormones, growth factors, and metabo-
lites. In vitro reports suggest that satellite cells may also
be regulated directly by specific dietary components
including ergogenic aids [18, 50, 62]. Determining the
factors that independently regulate satellite cells is import-
ant to understand overall mechanisms involved in muscle
growth and regeneration.This study focused on revealing possible molecular
mechanism underlying GO’s influence on skeletal myo-
blasts. For this purpose, transcriptomic profile analysis
of primary culture of equine satellite cells incubated with
GO was performed. This in vitro model can help to
identify and better understand potential therapeutic to
promote muscle regeneration in mammals, among them
also in sport horses.
Methods
Cell culture media and reagents
The following reagents/materials were used during cell
culture: GO powder was purchased from TCI Chemicals,
USA; Penicillinum crystalicum was purchased from Polfa
Tarchomin, Poland; and Dulbecco’s Modified Eagle’s
medium (DMEM) (1×) with Glutamax, fetal bovine serum
(FBS), horse serum (HS), and antibiotics (AB), penicillin-
streptomycin and amphotericin B, were purchased from
Gibco, Life Technologies, USA. Phosphate-buffered saline
(PBS), protease from Streptomyces griseus, and DMSO
were purchased from Sigma-Aldrich, USA. Primaria
tissue culture flasks (25 and 75 cm2) and Collagen I
Cellware six-well plates were purchased from Becton
Dickinson, USA.
Animals and muscle samples
Samples of semitendinosus muscle were collected from
six horses (6-month-old, healthy colts), aseptically in a
commercial abattoir during routine slaughter. Next, they
were dissected free of connective and adipose tissues to
minimize contamination with adipocytes and fibroblasts.
The tissue was sliced to pieces, washed four times in
PBS with gradually decreasing antibiotic concentration
(40,000 units (U) Penicillinum crystalicum/100 ml PBS,
20,000 U Penicillinum crystalicum/100 ml PBS), sus-
pended in sterile FBS with addition of 10 % DMSO,
gradually cooled down to −80 °C, and then stored in
liquid nitrogen until isolation.
Satellite cell isolation, cell culture, and experimental
design
Since the purpose of the study was to evaluate the im-
pact of GO on in vitro differentiation, primary satellite
cell cultures from semitendinosus muscle of all horses
were isolated and assessed for cell viability (MTT assay)
and fusion index (data not shown). For further analysis,
the cell line with the best scores was chosen.
To isolate equine satellite cells, six samples of semiten-
dinosus muscle were thawed in water bath in 37 °C,
centrifuged, and washed three times with PBS with Peni-
cillinum crystalicum. Then, each sample was incubated
(1.5 h) with DMEM/AB/protease from S. griseus (pH
7.3) and sieved in order to separate tissue debris. The
filtrates were centrifuged three times, resuspended in
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and transferred to polypropylene Petri culture disks. To
minimize possible fibroblast contamination, 1.5-h pre-
plating was used. Subsequently, supernatant containing
myoblasts was transferred to Primaria culture flasks.
The growth medium was changed every 2 days. On the
10th day of proliferation, cells were trypsinized and
counted by Scepter Cell Counter (Merck Millipore,
Germany). Equal number of cells (30,000) from each iso-
lation was transferred to separate the well of Collagen I
Cellware six-well plates. After obtaining 80 % of conflu-
ence, proliferation medium was replaced by differenti-
ation medium (2 % HS/DMEM/AB). Figure 1 presents
equine SC at various stages of growth. At the 48th hour
of differentiation, 0.125 μM GO was added and cells
were incubated for 24 h. Because GO is insoluble in
water, DMSO (0.04 μl/ml) was used as a vehicle. The
concentration of GO has been chosen on the basis of
assessing cell viability with 3-(4,5-dimethylthiazol-yl)-2-
5-diphenyltetrazolium bromide (MTT) colorimetric
assay (data not shown). Control medium contained
DMSO in the same dose as in GO-treated cells. Follow-
ing the GO treatment, medium from each plate was dis-
carded and plates were stored at −80 °C until further
analysis. Cell culture’s schema is illustrated in Fig. 2.
RNA isolation, validation, labeling, and hybridization
Total RNA (from GO-treated and control groups, n = 6)
was isolated according to the protocol supplied with the
miRNeasy Mini Kit (Qiagen, USA). RNA quantity was
measured spectrophotometrically using NanoDrop (Nano-
Drop Technologies, USA). The analysis of the final RNA
quality and integrity was performed with BioAnalyzer
2100 (Agilent Technologies, USA). To ensure optimal
microarray data quality, four RNA samples with the high-
est RIN ≥ 9.2 were included into the analysis.
Analysis of gene expression profile was performed using
Horse Gene Expression Microarray, 4 × 44 K (n = 4)
(Agilent Technologies, USA). Low Input Quick Amp
Labeling Kit (Agilent Technologies, USA) was used to
amplify and label total RNA (100 ng) to generate comple-
mentary RNA (cRNA). On each two-color microarray,
825 ng of cRNA from GO-exposed cells (labeled by Cy5,Fig. 1 Cultured equine satellite cells: sixth day of proliferation, 30 % conflu
differentiation (c). Myotubes are marked with arrowsn = 4) and 825 ng of cRNA from control cells (labeled by
Cy3, n = 4) were hybridized to the arrays (Gene Expression
Hybridization Kit, Agilent Technologies, USA) according
to the manufacturer’s protocol.
RNA Spike-In Kit (Agilent Technologies, USA) was
used as an internal control to efficiently monitor micro-
array workflow for linearity, sensitivity, and accuracy. Ac-
quisition and analysis of hybridization intensities were
performed using the Agilent DNA microarray scanner
and Agilent Feature Extraction software 10.7.3.1 according
to the standard manufacturer’s procedures and Linear
Lowess normalization (Cy5/Cy3 dye bias compensation).
The statistical analysis was performed using Gene
Spring 13 software (Agilent Technologies, USA) with de-
fault setting for two-color microarrays. The estimated
significance level (p value) was corrected for multiple
hypotheses testing using Benjamini and Hochberg false
discovery rate (FDR) adjustment. Messenger RNAs
(mRNAs) with FDR ≤ 0.05 and fold change (FC) ≥1.3
were selected as significantly differentially expressed.
The microarray experiment was performed according to
MIAME guidelines [6]. The data discussed in this publica-
tion have been deposited in NCBI’s Gene Expression
Omnibus [16] and are accessible through GEO Series ac-
cession number GSE73730 (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE73730).
cDNA synthesis and quantitative real-time PCR
To verify microarray results, the quantitative real-time
polymerase chain reaction (qPCR) method was applied.
The sequences of verified genes, complementary to those
on microarrays, were obtained from Ensembl database.
Primers were designed using Primer-Blast software (NCBI
database) and then checked for secondary structures using
Oligo Calculator (http://www.basic.northwestern.edu/bio-
tools/oligocalc.html). The secondary structures of the
amplicon were examined using m-fold Web Server (http://
mfold.rna.albany.edu/?q=mfold). The sequences of the
primers are listed in Table 1. The primers were purchased
from Oligo IBB (Polish Academy of Science, Warsaw,
Poland). Each primer pair was quality tested to ensure that
a single product was amplified (dissociation curve analysis)
and that there was no primer-dimer coupling.ence (a); 10th day of proliferation, 80 % confluence (b); and 48 h of
Fig. 2 Experiment design. Equine SC were cultured until reaching 80 % of confluence, and then proliferation medium was replaced by
differentiation medium. After the second day of differentiation, cells were incubated for 24 h with GO. Following the GO treatment,
differentiating cells were scraped and stored at −80 °C until further analysis
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control samples (n = 6) was reverse transcribed using
Trancription First-Strand cDNA Synthesis Kit (Roche,
USA). All analyses were performed on individual sam-
ples of total RNA using a SensiFAST SYBR lo-ROX
Kit (Blirt, Bioline, Poland) following the manufac-
turer’s protocol. Assays for each gene were conducted
in duplicate in a Stratagene Mx3005p thermal cycler
according to the following protocol: pre-incubation
for 2 min at 95 °C and amplification (40 cycles) con-
taining denaturation at 95 °C for 5 s and annealing at
a temperature specified in Table 1 for 15 s. Dissoci-
ation curve setting was as follows: denaturation at
95 °C for 0 s, annealing at a temperature specified in
Table 1, continuous melting up to 95 °C for 0 s
(slope = 0.1 °C/s), and cooling at 40 °C for 30 s.
Gapdh was used as a reference gene. The relative ex-
pression of the target gene was calculated according
to the following formula:
ΔΔCT ¼ ΔCT sampleð Þ−ΔCT controlð Þ
where ΔCT is the difference in CT between the tar-
geted gene and reference control. Results were calcu-
lated as 2−ΔΔCT [38] using GenEx 6.0 (MultiD Analyses,Table 1 Primers used for real-time qPCR; full names of genes are av
No. Gene symbol Forward primer Reverse prime
1. bdnf CCCCATGAAAGAAGCAAACG TACAAGTCCG
2. btg1 GGCTCCATCTGTGTGCTGTA GCCCACCCAA
3. gja1 TGCTGCGAACCTACATCATC CGATGACGTT
4. igf1 CAGAAGCAATGGGAAAAATCA CGTGGGCTTG
5. itpr2 CTGTGGGTATTCGGCCATTT GCCACGATTT
6. mllt3 GGAACCGAAACCCATGTCAA GGGCTTTTTGT
7. mstn GCCTGGAAACAGCTCCTAAC GTCGTCGCGT
8. myf5 GGAGACGCCTGAAGAAAGTC CCGGCAGGCT
9. myog CTCGCTCACCTCCATTGTG CAGTTGGGCA
10. tgfb2 AGTACTACGCCAAGGAGGTT TAGGCGGGAT
11. gapdh GTTTGTGATGGGCGTGAACC GTCTTCTGGGSweden). The amplification efficiency (E = 10(−1/slope) − 1)
was determined by performing a comparative quantita-
tion standard curve and was >0.9 for each target gene
and the reference gene. Standard curves were generated
using a four-point 1:10 dilution series starting with
cDNA representing 10 ng of input total RNA. qPCR
analysis has been conducted according to a standardized
approach [10].
Functional analysis
The list of significantly modulated by GO genes was an-
alyzed by Functional Analysis tool in the Database for
Annotation, Visualization and Integrated Discovery
(DAVID version 6.7) (da Huang et al. 2009) in order to
identify their annotations in gene ontology divided into
three functional classes: biological processes, cellular
components, and molecular functions. Gene ontology
enrichment was calculated by EASE score corrected
for multiple hypotheses testing using Benjamini and
Hochberg FDR.
Relationships between all differentially expressed genes
(microarray and RT-PCR) were visualized with Pathway
Studio’s Build Pathway functionality (Elsevier, USA)
which is based on the wave-propagation algorithm de-
veloped for the navigation through complex networks.ailable in Table 2
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Algorithm was used. Protein entity type and direct regu-
lation, regulation, expression, and promoter-binding re-
lationships were selected in the analysis. Such created
graph was expanded with five muscle-related biological
processes.
Results
The number of differentially expressed genes
Comparison of gene expression between GO-treated and
control cells revealed statistically significant (FDR ≤ 0.05,
FC ≥ 1.3) differences in the expression of 97 transcripts.
Sequences of differentially expressed probes not anno-
tated by microarray manufacturer were compared
with the NCBI nucleotide databases (using blastn) to
assign a gene name. Probes not matching in 100 %
with any eukaryotic mRNA/gene were excluded from
gene lists used for functional analysis. That resulted
in 58 identified, unduplicated, transcript IDs including
17 up- and 41 down-regulated genes in GO vs. con-
trol group. The list of identified transcripts can be
found in Table 2. All array data are plotted and
shown in Additional file 1.
In this paper, symbols of genes and their protein
products have been presented in their original form
referring to specificity of the cited paper, as lowercase
italic or uppercase letters, when they refer to tran-
scriptomic or proteomic research, respectively. In the
following discussion, arrows indicate up- (↑) or down-
regulation (↓) of gene expression. Validated (from
microarray) or tested (mstn, myog, igf1) by qPCR
genes are marked with hash (#).
Real-time qPCR
According to the ontological classification and available
literature, seven genes involved in the skeletal muscle
development, sarcomere development, actin binding,
and regulation of cell proliferation and differentiation
were selected for qPCR validation. Except for gap junc-
tion protein alpha 1 (gja1), all expression changes from
qPCR overlapped microarray results (Table 3, Fig. 3). In
our study, we focused on the impact of GO on muscle
development; thus, we also measured mRNA levels of
three genes from muscle development profile myog, igf1,
and mstn, which did not reach the FC ≥ 1.3 threshold
(Fig. 4).
Functional analysis
Significantly enriched gene ontologies retrieved from
DAVID output files are presented in Additional file 2. In
Table 4, selection of most significant biological processes
is shown (EASE score <0.001), providing a comprehen-
sive overview of important processes possibly induced
by GO in differentiating ESC.Using Pathway Studio’s Build Pathway algorithm, we
identified 116 relationships within selected entities,
which are displayed in a graph view on Fig. 4. Seventy of
identified relationships had the highest (third) confi-
dence level which means that the number of references
confirming this relationship was ≥3. Detected types of
regulation were regulation (86), expression (28), direct
regulation (1), and promoter binding (1). Fifty-five rela-
tions were positive, 22 negative, and 39 not defined.
Chosen relationships are further discussed in the follow-
ing chapter.Discussion
According to Fernyhough et al. [18], oral supplements
may affect myofibers in five potential ways: (1) by dir-
ect interaction, (2) by direct influence and producing
paracrine agents that affect SC, (3) by affecting SC,
(4) by producing hormones that exert indirect effects
in muscle cells, and (5) by protecting all cell types
against oxidative damage. Although, the exact mode
of GO action on muscles was not revealed, GO has
been previously postulated to act through mechanisms
4 [12, 44] and 5 [17, 49]. In further discussion, we
suggest that the direct interaction of GO with SC (3)
may be a part of its skeletal muscle-enhancing mech-
anism [63]. For this purpose, genes important for
myogenesis have been selected and are discussed in
four functional groups.Ontology of differentially expressed genes
According to functional analysis, the five most signifi-
cant biological processes induced by 24-h incubation
of differentiating equine SC with 0.125 μmol GO are
related to skeletal muscles; however, muscle organ de-
velopment is the only record showing significance
after FDR correction (Table 4). Moreover, GO influ-
enced genes associated with contractile apparatus de-
velopment (Additional file 2; CC and MF sheet). All
this together indicates that GO, indeed, may directly
influence SC activity and in vitro differentiation.
Other significantly enriched processes referred to
macromolecule metabolism and positive regulation of
transcription (Table 4). The last has also a confirm-
ation in enriched molecular functions: transcription
regulator activity and transcription cofactor activity
(Additional file 2; MF sheet). Functional analysis re-
vealed also that GO influenced growth factor activity
(Additional file 2; MF sheet). Axon and neuron
projection-related genes (Additional file 2; CC sheet)
could be connected with recent in vivo findings by
Eslami et al. [17] who suggested that GO-induced in-
crease in muscle strength may arise from neural ad-
aptations without altering muscle mass.
Table 2 List of differentially expressed genes in GO-treated vs. CTRL equine satellite cells—microarray analysis (FDR ≤ 0.05, fold
change ≥1.3, n = 4)
No. Gene symbol Regulation FC Corr. p value Description Accession number
1. il-1r2 Up 3.1 0.040 Interleukin-1 receptor type II [NM_001081816]
2. efhc2 Up 3.0 0.049 EF-hand domain (C-terminal) containing 2 [ENSECAT00000017638]
3. tcrd Up 2.2 0.050 T cell receptor delta [L38389]
4. tfap2e Up 1.8 0.039 Transcription factor AP-2 epsilon (activating enhancer-binding
protein 2 epsilon)
[ENSECAT00000003183]
5. cdca7 Up 1.7 0.027 Cell division cycle associated 7 [ENSECAT00000012017]
6. f2rl2 Up 1.6 0.048 Coagulation factor II (thrombin) receptor-like 2 [ENSECAT00000010830]
7. rcor2 Up 1.5 0.026 REST corepressor 2 [ENSECAT00000024786]
8. lrrc16a Up 1.5 0.049 Leucine-rich repeat containing 16A [ENSECAT00000026357]
9. mapk14 Up 1.5 0.037 Mitogen-activated protein kinase 14 [XM_005604060]
10. fezf2 Up 1.4 0.029 FEZ family zinc finger 2 [ENSECAT00000022391]
11. colec12 Up 1.4 0.026 Collectin subfamily member 12 [XM_005604060]
12. pir Up 1.4 0.038 Pirin (iron-binding nuclear protein) [ENSECAT00000014292]
13. gja1 Up 1.4 0.048 Gap junction protein 1 [ENSECAT00000005498]
14. itpr2 Up 1.4 0.05 Inositol 1,4,5-trisphosphate receptor, type 2 [ENSECAT00000009891]
15. tmem107 Up 1.3 0.045 Transmembrane protein 107 [ENSECAT00000014966]
16. steap1 Up 1.3 0.045 6 transmembrane epithelial antigen of the prostate
(metalloreductase)
[ENSECAT00000024982]
17. alcam Up 1.4 0.045 Activated leukocyte cell adhesion molecule [XM_005602026]
18. musk Down −1.3 0.042 Muscle, skeletal, receptor tyrosine kinase [ENSECAT00000010687]
19. exoc6 Down −1.3 0.044 Exocyst complex component 6 [ENSECAT00000025821]
20. sept6 Down −1.3 0.036 Septin 6 [XM_005614469]
21. mdh2 Down −1.3 0.039 Malate dehydrogenase 2, NAD (mitochondrial) [NM_001195526]
22. nexn Down −1.3 0.039 Nexilin (F-actin-binding protein) [ENSECAT00000016039]
23. setd7 Down −1.3 0.026 SET domain containing lysine methyltransferase 7 [ENSECAT00000020466]
24. tmem47 Down −1.3 0.045 Transmembrane protein 47 [XM_008544808]
25. bdnf Down −1.3 0.027 Brain-derived neurotrophic factor [NM_001081787]
26. snca Down −1.3 0.038 Synuclein, alpha (non A4 component of amyloid precursor) [ENSECAT00000016509]
27. actg2 Down −1.4 0.045 Actin, gamma 2, smooth muscle, enteric [ENSECAT00000020181]
28. btg1 Down −1.4 0.039 B cell translocation gene 1, antiproliferative [ENSECAT00000022009]
29. znf423 Down −1.5 0.045 Zinc finger protein 423 [ENSECAT00000000207]
30. aqp1 Down −1.5 0.027 Aquaporin 1 [XM_003364834]
31. bcl2l11 Down −1.5 0.035 BCL2-like 11 (apoptosis facilitator) [ENSECAT00000023850]
32. nr2f2 Down −1.5 0.040 Nuclear receptor subfamily 2, group F, member 2 [ENSECAT00000008488]
33. pak1 Down −1.5 0.050 CDC42 effector protein (Rho GTPase binding) 3 [ENSECAT00000019645]
34. cryab Down −1.5 0.035 Crystallin, alpha B [ENSECAT00000012936]
35. abra Down −1.5 0.045 Actin-binding Rho-activating protein [ENSECAT00000016765]
36. capn6 Down −1.5 0.038 Calpain 6 [ENSECAT00000011583]
37. herpud1 Down −1.5 0.045 Homocysteine-inducible, endoplasmic reticulum stress-inducible
(ubiquitin-like domain member 1)
[JL623642]
38. tmcc3 Down −1.6 0.033 Transmembrane and coiled-coil domain family 3 [ENSECAT00000012141]
39. tbc1d8 Down −1.6 0.027 TBC1 domain family, member 8 (with GRAM domain) [ENSECAT00000013116]
40. kiaa1958 Down −1.6 0.045 Protein-coding gene [ENSECAT00000008002]
41. neo1 Down −1.6 0.038 Neogenin 1 [ENSECAT00000026822]
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change ≥1.3, n = 4) (Continued)
42. lrrn1 Down −1.6 0.045 Leucine-rich repeat neuronal 1 [ENSECAT00000002791]
43. ctrc Down −1.6 0.044 Chymotrypsin C (caldecrin) [XM_008540961]
44. itgb1bp2 Down −1.6 0.048 Integrin beta 1-binding protein (melusin) 2 [ENSECAT00000016364]
45. stk17b Down −1.6 0.039 Serine/threonine kinase 17b (apoptosis-inducing) [JL616416]
46. hist1h4a Down −1.6 0.045 Chromosome 4 open reading frame 21 [ENSECAT00000006145]
47. camta1 Down −1.6 0.039 Calmodulin binding transcription activator 1 [ENSECAT00000022451]
48. kcnk12 Down −1.7 0.033 Potassium channel, subfamily K, member 12 [XM_008530912]
49. phactr3 Down −1.7 0.035 Phosphatase and actin regulator 3 [ENSECAT00000008448]
50. mllt3 Down −1.7 0.044 Myeloid/lymphoid or mixed-lineage leukemia
(trithorax homolog, Drosophila)
[ENSECAT00000025395]
51. tgfb2 Down −1.8 0.038 Transforming growth factor, beta 2 [ENSECAT00000017826]
52. scd5 Down −2.0 0.038 Stearoyl-CoA desaturase 5 [ENSECAT00000015537]
53. myf5 Down −2.0 0.039 Myogenic factor 5 [ENSECAT00000021416]
54. garem Down −2.0 0.039 GRB2 associated, regulator of MAPK1 [ENSECAT00000012124]
55. duoxa2 Down −2.2 0.026 Dual oxidase maturation factor 2 [ENSECAT00000015499]
56. ncald Down −2.2 0.044 Neurocalcin delta [XM_005613237]
57. kcnmb2 Down −2.5 0.036 Potassium large conductance calcium-activated channel,
subfamily M, beta member 2
[ENSECAT00000009305]
58. hla-dqb1 Down −5.0 0.028 Major histocompatibility complex, class II, DQ beta I [XM_008506652]
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Pre- and postnatal skeletal muscle development de-
pends on the expression of four basic helix-loop-helix
transcription factors called myogenic regulatory fac-
tors (MRFs). This group shares the ability to induce
myogenic differentiation when expressed in non-
muscle cells [43]. Three MRFs, myf5, myogenin
(myog), and myod, were investigated in our study, but
only two of them possessed significant changes in
expression.Table 3 Results of real-time qPCR analysis (n = 6)












myod −1.1 1.6E-01In adult skeletal muscle, the highest expression of myf5
is present in committed satellite cells and decreases when
progression to myocytes and myotubes occurs [4]. Like-
wise, in cultured equine SC, qPCR showed that myf5
mRNA levels were highest during intensive proliferation
and decreased dramatically at the onset of differentiation
[25]. Compared to control cells, 24-h incubation of equine
SC with GO induced down-regulation of myf5 (↓#). Ac-
cording to this observation, we suggest that GO could po-
tentially advance equine SC differentiation.Fig. 3 Results of qPCR validation of selected genes revealed in
microarray experiment (FDR≤ 0.05). Asterisks indicate the following
criteria of significance: *p≤ 0.05; **p≤ 0.01; and ***p≤ 0.001; (n = 6)
Fig. 4 Results of qPCR analysis of additional genes important for
myogenic differentiation of equine SC (FDR > 0.05). Asterisks indicate
the following criteria of significance: *p≤ 0.05; **p ≤ 0.01; and
***p ≤ 0.001; (n = 6)
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expression of myogenin (myog). That contributes to the
withdrawal of myoblasts from the cell cycle [55]. Un-
detectable during proliferation, Myog expression level is
highest when myocytes differentiate and fuse into myo-
tubes [25] and remains at a slightly lower level in adult
skeletal muscle cells [4]. Disregarded of this, additional
qPCR showed down-regulation of myog (↓#) mRNA in
experimental cells. Down-regulation of both MRFs may
indicate that GO actually inhibits myogenic differenti-
ation. Our experiment was performed, 48 h after chan-
ging proliferation medium to differentiation medium. At
this stage, proliferating myocytes begin to differentiate
and fuse. However, the exact cell cycle of experimental
cells remains unequal and undefined. Thus, it is possibleTable 4 Selected significantly enriched (EASE score p value <0.001)
No. Name # of genes p value G
1. GO:0007517—muscle organ development 10 6.6E-8 m
m
2. GO:0014706~striated muscle tissue
development
6 7.5E-5 m
3. GO:0060537—muscle tissue development 6 9.4E-5 m
4. GO:0007519—skeletal muscle tissue
development
5 1.0E-4 m
5. GO:0060538—skeletal muscle organ
development
5 1.0E-4 m












9. GO:0045941—positive regulation of
transcription
9 9.9E-4 m
nthat GO has multiple ways of action and by down-
regulation of myog, it delays terminal differentiation and
simulates proliferation of equine SC. Moreover, tran-
scription factors involved in myogenic lineage progres-
sion are not strictly acting in a linear manner but are
organized in complex feedback and feed-forward net-
works with other muscle development genes [4]. These
relationships will be discussed further in this paper.
Genes belonging to the transforming growth factor β
superfamily
Transforming growth factor β2 (tgf-β2) (↓#) belongs to a
subset of transforming growth factor β superfamily
members, which exert strong control over proliferation,
migration, and adhesion of satellite cells [35]. TGF-β2
delays myoblast differentiation while increasing cellular
proliferation. Molecular mechanism of TGF-β2 includes
an increased rate of degradation of myod (Schabort et al.
2009). However, it has not been examined whether a
similar relationship exists in equine skeletal muscle. In a
recent study, de Mello et al. [41] showed tgf-β2 mRNA
levels were high only in proliferative C2C12 cells and
began to decrease after differentiation induction. Tgf-β2
mRNA levels were 10-fold lower after 3 days of differen-
tiation that strongly agrees with our observations, which
indicate that GO down-regulated tgf-β2 (↓#) in equine
myoblast during the third day of differentiation, when
compared to control cells.
This result encouraged us to investigate another mem-
ber of transforming growth factor superfamily, playing a
key role in the negative regulation of muscle growth in
mammals: myostatin (mstn). Although microarray ana-
lysis did not passed FDR correction test, additionalgene ontologies, DAVID
enes Bonferroni Benjamini FDR
usk, cryab, mapk14, itgb1bp2, myf5,
stn, igf1, myog, nr2f2, tgfb2
5.92E-5 5.92E-5 1.03E-4
usk, mapk14, myf5, myog, nr2f2, tgfb2 0.06 0.03 0.12
usk, mapk14, myf5, myog, nr2f2, tgfb2 0.08 0.03 0.15
usk, mapk14, myf5, myog, nr2f2 0.08 0.02 0.16
usk, mapk14, myf5, myog, nr2f2 0.09 0.02 0.16
apk14, snca, myf5, gja1, mstn, igf1,
bra, myog, nr2f2, tfap2e, znf423, tgfb2
0.19 0.047 0.37
apk14, myf5, mstn, igf1, abra, myog,
r2f2, tfap2e, znf423, tgfb2
0.40 0.08 0.89
apk14, myf5, mstn, igf1, abra, myog,
r2f2, tfap2e, znf423, tgfb2
0.55 0.11 1.38
apk14, myf5, mstn, igf1, abra, myog,
r2f2, tfap2e, znf423
0.59 0.10 1.5
Szcześniak et al. Genes & Nutrition  (2016) 11:5 Page 9 of 14qPCR demonstrated decreased mstn (↓#) mRNA level in
GO vs. control cells. The deletion of myostatin in mice
induces dramatic and widespread increase in skeletal
muscle mass due to both muscle hypertrophy and hyper-
plasia [32], and it also cause double-muscling phenotype
of some cattle and sheep breeds [57]. Wicik et al. [67]
showed inhibitory effect of exogenous MSTN on differ-
entiating C2C12 myoblasts.
We suggest that decreased expression of these two
genes could contribute to the putative GO-mediated
muscle growth enhancement, by increasing differenti-
ation process. However, this needs to be reconciled with
decreased expression of differentiation marker myog.
Other genes involved in cell proliferation and
differentiation processes
Our interest was also focused on genes involved in cell
proliferation and differentiation, described in the litera-
ture as important for myogenesis.
Mitogen-activated protein 14 (mapk14) (↑) also called
p-38α belongs to one of the major regulators of gene
transcription and metabolism in response to oxidative,
energetic, and mechanical stress in skeletal muscle.
Chronic activation of MAPK14 signaling pathway has
been implicated in the development of adaptive and mal-
adaptive response in skeletal muscle pathologies, such as
diabetes [7] and protein catabolism [53], and physio-
logical states, such as growth and differentiation [34].
Mapk14 expression coincides with myog expression dur-
ing differentiation [8], which could potentially indicate
the role of GO in muscle differentiation; however, in our
study, expression of this genes was opposite.
According to the qPCR analysis, exposition of SC to
GO induced significant down-regulation of insulin-like
growth factor 1 (igf-1) (↓#). Igf-1 is, up to date, the only
known growth factor positively regulating proliferation
and differentiation of these cells [60]. IGF-1 can indir-
ectly affect satellite cells, by increasing the expression of
myf5, myog, and myod, and embryonic myosin heavy
chain [70] and decreasing expression of mstn [56]. Ana-
lysis of the relationships between the abovementioned
genes places igf-1 on the top of the signaling cascade
hypothetically induced by GO (Fig. 5). Thus, it may be
suggested that GO decreases expression of MRF through
the inhibition of igf-1 signaling. These findings are in
contrast with presumed abilities of GO.
Haddad and Adams [24] indicated that intact signaling
through MAPK is necessary for the development of
IGF-I-induced skeletal muscle hypertrophy in vivo.
However, in our study, this relationship was not ob-
served, as indicated by different changes in the expres-
sion of these two molecules. In contrast, Trendelenburg
et al. [66] showed that pro-inflammatory cytokines may
inhibit myoblast growth via p38 signaling activity. Thisobservation corresponds with up-regulation of interleu-
kin 1 receptor type II (il1r2) (↑) expression and MRF’s
down-regulation in our culture cells, suggesting that GO
can activate stress-related signaling in cultured cells.
Another gene deserving attention is gja1 (↓#) gene en-
coding gap junction protein alpha 1—component of
intercellular channels that provides a route for the diffu-
sion of low molecular weight particles from cell to cell.
Except for that, GJA1 affects cell proliferation and differ-
entiation in various tissues. Although not present in nor-
mal adult skeletal muscle, GJA1 is necessary during
regenerative myogenesis in rodents [1, 21]. The relation-
ship between gja1 and MRF expression was observed in
the L6 myogenic cell line; pharmacological gap junction
blockers were found to inhibit myogenin expression and
myotube formation, reversibly [3]. Likewise, delayed ex-
pression of myog was found in myoblast cultures pre-
pared from mice with an inducible deletion of gja1 [1].
Similar function in differentiating myoblasts was re-
ported for B cell translocation gene 1 (btg1) (↓#). The
btg1 overexpression inhibited proliferation of several cell
lines including NIH3T3, PC12, and QM7 quail myoblast
lines [52]. Therefore, it was initially believed that these
proteins possess antiproliferative properties. However,
other studies demonstrated that btg1 up-regulation is
crucial at the onset of myoblast differentiation [54].
More recently, Busson et al. [9] described the molecular
basis of btg1 action and proved that it stimulates the
activity of not only MRFs but also nuclear receptors
already known as positive myogenic regulators (T3 and
all-trans retinoic acid receptors).
From all these studies, it becomes evident that the out-
come of gja1 and btg1 expression in muscle cells is associ-
ated with the onset of differentiation while irreversible
withdrawal from the cell cycle occurs. Thus, the context
of the signal is essential for understanding their role in
GO signaling. Taking into account that GO was added to
differentiating myoblasts, gja1 and btg1 down-regulation
indicate that GO may decrease equine myoblast fusion
and could suggest pro-proliferative action of btg1 and gja1
in equine SC exposed to GO, which agrees with the
reduced levels of MRF’s expression.
Herein, we demonstrate down-regulation of brain-
derived neurotrophic factor (bdnf ) (↓#). Bdnf is a mem-
ber of the mammalian family of neurotrophins, studied
for their roles in the nervous system function [13]. Fur-
ther expression-profiling studies have shown that bdnf is
differentially expressed in skeletal muscle under various
physiological and pathological conditions [11] but bdnf
expression pattern in certain physiological states
remained elusive. Mousavi and Jasmin [45] showed that
bdnf expression during myogenic differentiation has
been significantly reduced. Moreover, siRNA knockdown
of bdnf expression evoked precocious differentiation of
Fig. 5 Relationships between differentially expressed genes, based on Pathway Studio. Genes are marked with red and blue colors for up- and
down-regulation, respectively. The pathway was enriched with myogenesis-related biological processes and additional qPCR-tested genes of
muscle development profile (mstn, igf1, myog). Genes validated or tested by qPCR are highlighted
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tion of recombinant bdnf. However, more recently, Clow
and Jasmin [13] indicated that instead of its inhibitory
role, bdnf−/− mice demonstrated impaired induction of
several molecular markers of regeneration, including
pax7, myod, and myog when proliferating myoblasts
began to differentiate and fuse to repair damaged myofi-
bers. The role of bdnf remains questionable; however, at-
tenuated MRF’s expression in our culture may confirm
that expression of this gene is required for normal myo-
genic differentiation. This finding can also be applied to
the next specified molecule down-regulated by GO: αβ-
crystallin (cryab), (↓) a small heat shock protein involved
in preventing protein aggregation. Expression of cryabwas induced selectively in myoblasts during an early
stage of their differentiation in vitro [33]. Moreover,
mice lacking αβ-crystallin died prematurely with exten-
sive muscle wastage [59] which indicates its essential
role during myogenesis. Indeed, the αβ-crystallin pro-
moter contains canonical skeletal muscle-specific E-box
element that binds MRFs [20]. On the other hand,
overexpression of cryab inhibits myogenic differenti-
ation by negatively regulating differentiation-related
apoptosis, inhibiting caspase-3 activation and altering
myod levels [33, 59].
Next, gene affected by the presence of GO which de-
serves attention is nuclear receptor 2F2 (nr2f2) (↓#) alias
chicken ovalbumin upstream promoter transcription
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of the steroid-thyroid hormone receptor superfamily. Re-
cently, growing evidence suggests the pivotal role of
COUP-TFs in mesenchymal stem cell (MSC) regulation
and development [69]. As illustrated both in vitro and
in vivo, loss of COUP-TFII reprograms the precursors
by shifting the cell identity to osteogenic and myogenic
lineages at the expense of adipogenic and chondrogenic
programs, supporting the notion that COUP-TFII is es-
sential for fate choice and commitment [68]. The mo-
lecular mechanism by which COUP-TFII affects MSC
development is, at least partially, through the down-
regulation of Wnt cascade substrate: Wnt10b. This
phenomenon resulted in reduced fat tissue and en-
hanced glucose tolerance and insulin sensitivity, as well
as increased bone mineralization and muscle mass in
COUP-TFII-deficient mice [68]. Moreover, previous re-
ports indicated that COUP-TFII inhibits myogenesis by
the transcriptional and posttranscriptional regulation of
myod [2, 46]. In conclusion, down-regulation of this gene
may indicate that GO stimulates in vitro myogenesis.
Finally, in our study, increased expression (↑) of acti-
vated leukocyte cell adhesion molecule (alcam), also
known as cluster of differentiation 166 (CD166), has
been detected. Alcam plays an important role in cell
proliferation and the differentiation of mesenchymal tis-
sues in multiple species [61]. Moreover, alcam may in-
crease cell survival in several tumor types as well as
monocytes [61]. These abilities may result from the anti-
apoptotic capacity of this protein [39]. Other authors
speculate that ALCAM-ALCAM interactions, in cooper-
ation with other adhesion molecules, facilitate stroma
progenitor cell contact, resulting in proliferation of pro-
genitor cell subsets [47]. It may be presumed that ex-
pression of alcam could mediate GO action on SC, but
the functional roles in muscle physiology of this marker
remains unknown and needs further investigation.
Other genes positively regulating muscle differenti-
ation, whose expression was changed by GO, include
neogenin (Neo1) (↓), actin-binding Rho-activating
protein (Abra) (↓), actin γ-2 (actg2) (↓), integrin beta-1-
binding protein 2 (melusin 2, Itgb1bp2) (↓), muscle-
specific tyrosine kinase receptor (Musk) (↓), nexilin
(nexn) (↓), histone H3-K4 methyltransferase (setd7) (↓),
and calpain 6 (capn6) (↓)-myogenesis-suppressing gene
[5, 14, 27, 36, 37, 42, 64, 65]. Down-regulation of these
genes may suggest that 24-h incubation with 0.125 μM
of GO decreased differentiation of equine satellite cells.
Other gamma-oryzanol treatment-related genes
GO has been reported to possess strong antioxidant
activity; thus, it is postulated that GO might enhance
endurance and muscle-building capacity by hindering
the production of free radicals, which in theory couldlessen muscle exhaustion and fatigue in reaction to
anaerobic exercise [17]. Consistent with this, signifi-
cantly lower post-exercise total antioxidant status and
thiobarbituric acid-reactive substance level were ob-
served in racing horses receiving GO compared to
horses from other groups [49]. GO’s influence on oxi-
dative stress-related genes has been shown in other
tissues [30, 31]. However, in our study, gene ontology
analysis did not show any significant involvement of
differentially expressed genes in antioxidative pro-
cesses. It will be important in future studies to deter-
mine if antioxidant activity is involved in the
protective effects of GO under oxidative stress
conditions.
Lowered expression of stearoyl-CoA desaturase and
isoform 5 gene (scd5) (↓) as well as of coup-tfII (↓)
may reflect positive influence of GO on energy
homeostasis in skeletal muscle. As mentioned before,
Coup-tfII-deficient mice demonstrated reduced fat tis-
sue and enhanced glucose tolerance and insulin sensi-
tivity [68]. Likewise, SCD deficiency is evidenced to
activate metabolic pathways which promote β-
oxidation and decrease lipogenesis both in the liver
and skeletal muscles. SCD mutation results also in
general changes in the expression of genes involved
in lipid metabolism. SCD1-deficient mice have in-
creased energy expenditure and reduced body adipos-
ity and are resistant to diet-induced obesity (Dobrzyn
and Ntambi 2005). These results may confirm GO
utility in the treatment of diabetes (Ohara et al. 2009)
as well as positive effect on lean body mass gain.
Conclusions
In conclusion, we demonstrated for the first time that
GO can affect the transcriptomic profile of equine
satellite cells in vitro. Many of differentially expressed
genes are reported to be crucial for skeletal muscle
development. Analysis of expression changes proves
that various processes are reinforced by GO in equine
SC (Fig. 6); however, inhibition of myoblast differenti-
ation is prevailing observation. Incubation with GO
was performed at the onset of differentiation; thus,
decreased expression of differentiation markers may
indicate that GO delays this process in cultured
equine SC that may contribute to increased field of
cells that will later differentiate into myotubes. This
could be explained in further investigation of GO’s in-
fluence on satellite cells in proliferation stage. Beyond
this, 24-h incubation with GO induced different
expression of genes responsible for stress response,
increased myogenic lineage commitment, cell prolifer-
ation and differentiation, and finally positive influence
on energy homeostasis. Our study may confirm puta-
tive muscle-enhancing abilities of GO; however,
Fig. 6 Processes reinforced in equine satellite cells incubated with 0.125 μM of GO for 24 h
Szcześniak et al. Genes & Nutrition  (2016) 11:5 Page 12 of 14analysis of changes in gene expression did not give
equivocal results. Gene transcription is only one step
in the regulatory pathway that leads to the functional
protein synthesis. Our results encourage for investiga-
tion of GO-skeletal muscle relation in proteomic and
biochemical level in the future. The collective role of
GO in skeletal myogenesis remains unclear and needs
further investigation.
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